Stoke Therapeutics Reports Third Quarter 2025 Results and Highlights Clinical and Corporate Progress Toward Transformational RNA Medicines Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering the use of RNA-based…
Catalent Showcases SMARTag® ADC Pipeline Progress and New Enhanced Conjugate Class at 16th World ADC San Diego Catalent, Inc., a global leader in contract development and manufacturing services for advanced…
enGene Honored by BioSpace as a 2026 Best Place to Work, Underscoring Strong Culture and Mission-Driven Innovation enGene Holdings Inc. (“enGene” or the “Company”) (Nasdaq: ENGN), a clinical-stage, non-viral genetic…
QIAGEN to Acquire Parse Biosciences, Expanding Portfolio into Scalable Single-Cell Sequencing and AI-Driven Discovery QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that it has entered into a definitive agreement…
NMDP and CIBMTR to Present Research Advancing Transplant Access and Cell Therapy Innovation at ASH 2025 NMDP℠, a leading global nonprofit dedicated to advancing cell therapy, and the CIBMTR® (Center…
PharmaJet to Showcase Advancements in Intradermal Needle-Free Delivery at ASTMH Annual Meeting PharmaJet®, a leading company focused on transforming injectable delivery through needle-free technology, announced that it will present new…
Zetagen Therapeutics Announces Presentation of Promising Phase 2a Data Demonstrating Complete Responses in Metastatic Breast Cancer Bone Lesions at 2025 SABCS Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company developing…
Serenity Mental Health Centers Expands Access to Breakthrough Ketamine Treatment in Colorado Springs Serenity Mental Health Centers, one of the nation’s fastest-growing providers of advanced psychiatric care, has announced the…
Zoetis Appoints Kevin Esch as New R&D President to Succeed Rob Polzer in 2026, Marking a Strategic Leadership Transition in Global Animal Health Innovation Zoetis Inc. (NYSE: ZTS), the world’s…
Vertex Pharmaceuticals Reports Robust Third Quarter 2025 Results and Refines Full-Year Outlook as Pipeline Momentum Accelerates Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), a global leader in genetic and transformative medicine, today…
Genetix Biotherapeutics to Highlight U.S. Gene Therapy Implementation and Patient Experience Data at ASH 2025 Genetix Biotherapeutics Inc. announced that an analysis of recent patient experience data from the U.S.…
PureTech’s Gallop Oncology to Present Promising Phase 1b Data of LYT-200 in Relapsed/Refractory AML at the 2025 ASH Annual Meeting PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the…